CannLabs, Inc. Logo

CannLabs, Inc.

CANL

(0.0)
Stock Price

0,00 USD

0% ROA

0% ROE

0x PER

Market Cap.

1.026.482,00 USD

0% DER

0% Yield

0% NPM

CannLabs, Inc. Stock Analysis

CannLabs, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

CannLabs, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Negative ROE (-3013.34%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

2 ROA

The stock's ROA (-122.17%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

3 PBV

The stock's high Price-to-Book Value (P/BV) ratio (687.2x) suggests it's overvalued, potentially making it an expensive investment.

4 DER

The company has a high debt to equity ratio (239756%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

CannLabs, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

CannLabs, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

CannLabs, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

CannLabs, Inc. Revenue
Year Revenue Growth
2009 14.192
2010 48.497 70.74%
2011 16.161 -200.09%
2012 146.150 88.94%
2013 84.300 -73.37%
2014 1.364.760 93.82%
2015 1.881.952 27.48%
2016 1.364.760 -37.9%
2017 1.364.760 0%
2018 1.364.760 0%
2019 2.498.658 45.38%
2020 2.765.236 9.64%
2021 3.181.206 13.08%
2022 4.391.248 27.56%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

CannLabs, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2009 0
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 72 100%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

CannLabs, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2009 15.441
2010 81.296 81.01%
2011 0 0%
2012 140.619 100%
2013 141.749 0.8%
2014 3.004.719 95.28%
2015 4.618.892 34.95%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

CannLabs, Inc. EBITDA
Year EBITDA Growth
2009 -285
2010 -32.799 99.13%
2011 -120.226 72.72%
2012 5.531 2273.68%
2013 -57.449 109.63%
2014 -2.958.240 98.06%
2015 -4.455.860 33.61%
2016 -2.958.260 -50.62%
2017 -2.958.260 0%
2018 -2.958.260 0%
2019 810.560 464.96%
2020 530.780 -52.71%
2021 722.710 26.56%
2022 880.660 17.94%
2023 0 0%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

CannLabs, Inc. Gross Profit
Year Gross Profit Growth
2009 14.192
2010 48.497 70.74%
2011 16.161 -200.09%
2012 146.150 88.94%
2013 84.190 -73.6%
2014 478.114 82.39%
2015 523.288 8.63%
2016 -1.259.072 141.56%
2017 478.114 363.34%
2018 478.114 0%
2019 1.446.777 66.95%
2020 1.245.774 -16.13%
2021 1.698.343 26.65%
2022 2.062.523 17.66%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

CannLabs, Inc. Net Profit
Year Net Profit Growth
2009 -46.682
2010 -79.734 41.45%
2011 -155.319 48.66%
2012 -27.775 -459.2%
2013 -79.031 64.86%
2014 -1.584.218 95.01%
2015 -100.432 -1477.4%
2016 -1.584.218 93.66%
2017 -1.584.218 0%
2018 -1.584.218 0%
2019 803.582 297.14%
2020 520.571 -54.37%
2021 712.797 26.97%
2022 869.171 17.99%
2023 0 0%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

CannLabs, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2009 0
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

CannLabs, Inc. Free Cashflow
Year Free Cashflow Growth
2009 -14.207
2010 -30.085 52.78%
2011 -12.240 -145.79%
2012 -56.190 78.22%
2013 -51.006 -10.16%
2014 -1.617.042 96.85%
2015 -500.977 -222.78%
2016 -1.617.042 69.02%
2017 -1.617.042 0%
2018 -1.617.042 0%
2019 550.619 393.68%
2020 570.733 3.52%
2021 533.389 -7%
2022 772.608 30.96%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

CannLabs, Inc. Operating Cashflow
Year Operating Cashflow Growth
2009 -14.207
2010 -30.085 52.78%
2011 -12.240 -145.79%
2012 -56.190 78.22%
2013 -50.936 -10.31%
2014 -1.257.271 95.95%
2015 -469.301 -167.9%
2016 -1.257.271 62.67%
2017 -1.257.271 0%
2018 -1.257.271 0%
2019 550.619 328.34%
2020 570.733 3.52%
2021 533.389 -7%
2022 772.608 30.96%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

CannLabs, Inc. Capital Expenditure
Year Capital Expenditure Growth
2009 0
2010 0 0%
2011 0 0%
2012 0 0%
2013 70 100%
2014 359.771 99.98%
2015 31.676 -1035.78%
2016 359.771 91.2%
2017 359.771 0%
2018 359.771 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

CannLabs, Inc. Equity
Year Equity Growth
2009 71.509
2010 66.775 -7.09%
2011 29.829 -123.86%
2012 2.054 -1352.24%
2013 104.385 98.03%
2014 -1.628.971 106.41%
2015 493.466 430.11%
2016 -1.628.971 130.29%
2017 -1.628.971 0%
2018 -1.628.971 0%
2019 1.862.380 187.47%
2020 1.919.139 2.96%
2021 2.193.637 12.51%
2022 2.402.808 8.71%
2023 0 0%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

CannLabs, Inc. Assets
Year Assets Growth
2009 190.316
2010 152.582 -24.73%
2011 87.377 -74.62%
2012 32.000 -173.05%
2013 209.884 84.75%
2014 1.317.627 84.07%
2015 1.125.655 -17.05%
2016 1.317.627 14.57%
2017 1.317.627 0%
2018 1.317.627 0%
2019 2.187.797 39.77%
2020 2.701.798 19.02%
2021 2.982.594 9.41%
2022 3.248.924 8.2%
2023 0 0%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

CannLabs, Inc. Liabilities
Year Liabilities Growth
2009 118.807
2010 85.807 -38.46%
2011 57.548 -49.11%
2012 29.946 -92.17%
2013 105.527 71.62%
2014 2.946.598 96.42%
2015 3.501.578 15.85%
2016 2.946.598 -18.83%
2017 2.946.598 0%
2018 2.946.598 0%
2019 325.417 -805.48%
2020 782.659 58.42%
2021 788.957 0.8%
2022 846.116 6.76%
2023 0 0%

CannLabs, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
0
Price to Earning Ratio
0x
Price To Sales Ratio
0x
POCF Ratio
0
PFCF Ratio
0
Price to Book Ratio
0
EV to Sales
0
EV Over EBITDA
0
EV to Operating CashFlow
0
EV to FreeCashFlow
0
Earnings Yield
0
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0
Graham NetNet
0

Income Statement Metrics

Net Income per Share
0
Income Quality
0
ROE
0
Return On Assets
0
Return On Capital Employed
0
Net Income per EBT
0
EBT Per Ebit
0
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0
Return on Tangible Assets
0
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0
Current Ratio
0
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

CannLabs, Inc. Dividends
Year Dividends Growth

CannLabs, Inc. Profile

About CannLabs, Inc.

CannLabs, Inc. provides cannabis testing laboratory services in the United States. Its testing services include potency testing, residual solvent analysis, microbiological testing, pesticide testing, heavy metals testing, nutrient analysis, terpenes analysis, shelf-life/stability studies, gene expression testing, and genotyping/phenotyping testing. The company also offers data/analytics and consulting, as well as education services. CannLabs, Inc. is based in Denver, Colorado.

CEO
Mr. Mark C. Mirken
Employee
37
Address
3888 East Mexico Avenue
Denver, 80210

CannLabs, Inc. Executives & BODs

CannLabs, Inc. Executives & BODs
# Name Age
1 Mr. Mark C. Mirken
Chairman & Chief Executive Officer
70

CannLabs, Inc. Competitors